No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
Control exclude
DIABETES_FG
Extra metadata
First used in FinnGen datafreeze
DF2
Similar endpoints
↥List of similar endpoints to
Diabetes, insuline treatment (Kela reimbursement)
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 602906 | 276902 | 320556 |
| Only index persons | 495693 | 225945 | 269748 |
| Unadjusted period prevalence (%) | |||
| Whole population | 8.46 | 7.93 | 8.96 |
| Only index persons | 9.39 | 8.31 | 10.30 |
| Median age at first event (years) | |||
| Whole population | 61.43 | 63.68 | 59.51 |
| Only index persons | 60.80 | 62.74 | 59.18 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 68356 | 30040 | 38316 |
| Unadjusted period prevalence (%) | 15.97 | 11.80 | 19.24 |
| Median age at first event (years) | 58.98 | 58.57 | 59.31 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Mortality – FinRegistry
↥Association
Association between endpoint KELA_DIAB_INSUL_EXMORE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| KELA_DIAB_INSUL_EXMORE | 1.342 [1.24, 1.45] | < 0.001 |
| Birth year | 0.993 [0.98, 1.0] | 0.085 |
During the follow-up period (1.1.1998 — 31.12.2019), 43559 out of 189552 females with KELA_DIAB_INSUL_EXMORE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| KELA_DIAB_INSUL_EXMORE | 1.473 [1.35, 1.6] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 54387 out of 230052 males with KELA_DIAB_INSUL_EXMORE died.
Mortality risk
Mortality risk for people of age
years, who have KELA_DIAB_INSUL_EXMORE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.1% | 0.242% |
| 5 | 0.643% | 1.48% |
| 10 | 1.571% | 3.6% |
| 15 | 3.03% | 6.827% |
| 20 | 5.392% | 11.443% |
Relationships between endpoints
↥Index endpoint: KELA_DIAB_INSUL_EXMORE – Diabetes, insuline treatment (Kela reimbursement)
GWS hits: 215
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
Extremity
rg [CI]
Extremity
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data